19287-55-9

Upstream product

• 95201-25-5 ethyl 2-(4-methoxyphenyl)quinoline-4-carboxylate 
• 1369590-97-5 (2-(4-methoxyphenyl)quinolin-4-yl)(pyridin-2-yl)methanone 
• 1369590-98-6 (2-(4-methoxyphenyl)quinolin-4-yl)(pyridin-2-yl)methanol 
• 4364-02-7 2-(4-methoxyphenyl)quinoline-4-carboxylic acid 
• 91-56-5 indole-2,3-dione 
• 51842-72-9 methyl 2-(4-methoxyphenyl)quinoline-4-carboxylate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 

Downstream Products

• 1384275-34-6 threo-tert-butyl 2-(hydroxy(2-(4-methoxyphenyl)quinolin-4-yl)methyl)piperidine-1-carboxylate 
• 1384275-41-5 erythro-tert-butyl 2-(hydroxy(2-(4-methoxyphenyl)quinolin-4-yl)methyl)piperidine-1-carboxylate 
• 858474-14-3 (1S,2S)-(2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol hydrochloride 
• 858474-14-3 (1R,2R)-(2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol hydrochloride 
• 858474-14-3 (1S,2R)-(2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol hydrochloride 
• 858474-14-3 (1R,2S)-(2-(4-methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol hydrochloride 
• 1384275-32-4 C₂₇H₃₂N₂O₄ 

Relevant academic research and scientific papers

COMPOUNDS AND USE FOR TREATING CANCER

The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

IDENTIFICATION OF NSC23925 ISOMERS TO REVERSE MULTIDRUG RESISTANCE IN HUMAN CANCERS

This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same.

Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2- piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer

Development of multidrug resistance (MDR) during chemotherapy is a fundamental obstacle associated with cancer care. Prior studies have identified (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (5) (NSC23925) to be a small molecule agent that r